9 results
Primary objective: to explore 18F-FDHT PET/CT as a predictor of response in patients with metastasized CRPC to be treated with enzalutamide. Secondary objective: to explore 18F-FDHT PET/CT as a predictor of clinical survival endpoints in patients…
To investigate the influence of concomitant enzalutamide on the pharmacokinetics of cabazitaxel.
The purpose of Part A is to investigate how quickly and to what extent Rizatriptan in DFN-10 is absorbed and eliminated from the body (this is called pharmacokinetics). In addition, it will be investigated to what extent DFN-10 is tolerated.In Part…
The purpose of this study is to evaluate the efficacy and safety of MDV3100, a novel potent androgen-receptor antagonist without known agonist activity, in asymptomatic or mildly symptomatic patients with progressive metastatic prostate cancer who…
1. To assess the effects of 3 months neoadjuvant androgen ablation with enzalutamide on the surgicial margin status of men with non-metastasized prostate cancer.2. To properly evaluate the effects of androgen ablation on gene expression, analyses of…
Primary Objectives:To explore whether the decrease in a panel of early easily assessable biomarkers (PSA-mRNA, PCA3-mRNA and TMPRSS2:ERG gene fusion-mRNA, (currently under development) ARv7 mRNA, ARwt mRNA, miR-21, miR-141, miR-200a, miRrumc95,…
To compare treatment with enzaluatmide plus BI836845 with treatment with enzalutamide only.
The aim of this study is to analyse the analgetic effect of a local injection in the lateral femoral cutaneous nerve ( LFCN) with methylprednisolone/lidocaine (M/L) after localisation through elektro stimulation VS placebo. In this trial we hope to…
1. To evaluate the feasibility of 18F-FDG PET/CT, or WB MRI or both to determine metastatic tumour load before and after treatment with Enzalutamide in CRPC patients. 2. To evaluate how these 2 imaging modalities perform compared to traditional…